Recalled medicines and products GIF — current list 2026
GIF — Chief Pharmaceutical Inspectorate
GIF (the Chief Pharmaceutical Inspectorate) issues decisions to suspend and withdraw medicines and pharmaceutical products from the market when quality, safety or batch problems arise. The list below brings together medicines recalled by the Chief Pharmaceutical Inspectorate in one place and is updated continuously.
353 alerts in the database • last update:
Latest recalled products from GIF
Symibace
Given the test results indicating significant exceedances of the specification limit for the content of impurity B, the health risk to humans from keeping these medicinal product batches on the market is real and likely. Potential effects: possible poisoning, increased adverse reactions, lack of treatment safety.
Symibace
Given the test results indicating significant exceedance of the specification limit for impurity B content, the threat to human health from leaving these batches of the medicinal product on the market is real and likely. Potential effects: poisoning, adverse reactions, cardiovascular complications.
Corsib
Unidentified degradation impurities of the active substance pose a real and direct threat to patients; due to their unconfirmed nature, a risk to the patient’s health and life cannot be excluded. Potential effects: severe adverse reactions, complications, life‑threatening events.
APAP dla dzieci FORTE
The suspension contains gas bubbles, is foamy and completely or almost completely fills the bottle, preventing shaking, homogenization and correct dosing of the medicinal product. Potential effects: improper dosing of paracetamol, lack of efficacy or overdose, possible adverse reactions.
Syldenafilu cytrynian
If the description of the primary packaging of the pharmaceutical substance does not match its actual content, there is a risk of using the wrong substance in compounding a prescription medicine. An incorrect expiry date may lead to use beyond the period with guaranteed efficacy and safety. Potential effects: lack of treatment efficacy, adverse reactions, complications.
Oxylaxon
Failure of the medicinal products to meet the specified quality requirement manifests as excessively high content of one of the two active substances, oxycodone hydrochloride, which may expose patients to receiving a substandard medicinal product. Potential effects: excessive opioid effect, serious adverse reactions, complications of pain therapy.
Oxylaxon
In this case, the failure of the medicinal products to meet their specified quality requirement manifests as an excessively high content of one of the two active substances, i.e. oxycodone hydrochloride. Potential effects: opioid overdose, increased adverse reactions, risk to the patient’s health.
Oxylaxon
A quality defect was identified involving excessively high oxycodone hydrochloride content in certain Oxylaxon prolonged-release tablet batches, caused by abnormal parameters of granulate batch EE03807. Potential effects: opioid overdose, respiratory depression, poisoning.
Benodil
The quality defect consists in labelling Benodil 0.25 mg/ml ampoules with Budixon Neb 0.5 mg/ml labels, which may mislead regarding the dose and use of the medicine. Potential effects: incorrect dosing, lack of therapeutic efficacy, or risk of complications in patients requiring an accurate corticosteroid dose.
Linezolid Polpharma
Incorrect release of the active substance from the medicinal product, to an extent that may affect its therapeutic properties, constitutes a real risk to patients' health due to the potential lack of efficacy. Potential effects: ineffective treatment of infections, risk of disease progression or complications.
Temozolomide Sun
Stability testing showed that the product does not meet quality specification requirements for active substance content; the content is reduced below the lower acceptance limit, which affects the product’s effectiveness. Potential effects: reduced treatment efficacy, possible lack of therapeutic effect.
Mebelin
Testing by the National Medicines Institute showed that the product does not meet quality requirements: release of mebeverine hydrochloride after 2, 8 and 12 hours was below the lower acceptance limit, which affects the effectiveness of the medicine. Potential effects: reduced effectiveness in treating intestinal complaints and possible worsening of disease symptoms.
Ozempic
Leaving a falsified medicinal product on the market poses a direct and real threat to patients’ health and potentially life; there is no confirmation of its actual composition or its effect on the medicine’s action. Potential effects: poisoning, lack of treatment efficacy, severe complications, life-threatening events.
Ozempic
Keeping a falsified medicinal product on the market poses a direct and real threat to health and potentially also to patients’ lives; the lack of confirmed composition makes it impossible to predict its effect on pharmacological action and treatment safety. Potential effects: poisoning, lack of treatment efficacy, serious adverse reactions.
Ozempic
Keeping a falsified medicinal product on the market poses a direct and real threat to patients’ health and potentially life; there is no confirmation of the actual composition of the falsified product or its impact on pharmacological, immunological or metabolic action. Potential effects: poisoning, lack of treatment efficacy, severe complications.
Ozempic
Keeping the falsified medicinal product on the market poses a direct threat to patients’ health and potentially life, because there is no confirmation of the actual composition of the medicine and its impact on pharmacological, immunological or metabolic action cannot be predicted. Potential effects: poisoning, lack of efficacy, severe complications.
Dexamytrex
Unidentified microbiological contamination of the active substance (gentamicin sulfate) was detected, posing a real and direct risk to patients and potentially adversely affecting the efficacy and safety of use of the eye ointment. Potential effects: eye infections, infectious complications, reduced treatment effectiveness.
Ozempic
Keeping a falsified medicinal product on the market poses a direct and real threat to patients’ health and potentially to life; there is no confirmation of the actual composition of the falsified product or its impact on pharmacological action. Potential effects: poisoning, lack of treatment efficacy, severe complications.
Tranexamic acid injection BP
A quality defect was found: the ampoule cannot be opened normally, it crumbles, and it is uncertain whether glass fragments have entered the inside and contaminated the solution, creating a risk of administering a medicinal product containing glass to the patient. Potential effects: poisoning, tissue damage, life-threatening complications.
Vendal retard
Due to morphine being released in a different amount than specified in the documentation, the impact on the course of therapy and the suspicion of a threat to the patient’s health or life cannot be excluded. Potential effects: overdose or insufficient analgesic effect, dependence, life-threatening complications.
Aciclovir Jelfa
Due to the detected presence of particles visible to the naked eye, a risk to the patient’s health or life cannot be excluded. Potential effects: complications after intravenous administration, vessel damage, embolism, severe systemic reactions.
Tresuvi
The presence of unidentified solid particles was found in the product, and the nature of the contamination and its cause have not been determined. Therefore, a risk to the patient’s health and life cannot be excluded. Potential effects: infusion complications, embolism, inflammatory reactions, life‑threatening events.
Ibuprofen B. Braun
Cross-contamination of infusion solutions was found in the listed batches of B. Braun medicinal products, reported via the Rapid Alert system by the Hessisches Landesamt für Gesundheit und Pflege as potentially endangering the safety of intravenous therapy. Potential effects: poisoning, severe adverse reactions, lack of efficacy, treatment complications.
Ibuprofen B. Braun
Cross-contamination of infusion solutions in the listed batches of B. Braun medicinal products was detected and reported via the Rapid Alert system by the German pharmaceutical authority. Potential effects: possible severe adverse reactions, poisoning, lack of therapeutic efficacy or infusion-related complications.
Ibuprofen B. Braun
Cross-contamination of infusion solutions in selected batches of medicinal products was found, which may result in administration of an unintended active substance to the patient and complications during intravenous treatment. Potential effects: poisoning, severe adverse reactions, lack of treatment efficacy.
Paracetamol B. Braun
detection of cross-contamination of infusion solutions in the above-mentioned series of medicinal products Potential effects: poisoning, unpredictable adverse reactions, lack of therapeutic efficacy, perioperative complications.
Metronidazole B. Braun
Cross-contamination of infusion solutions in the listed batches of B. Braun medicinal products was detected. Potential effects: poisoning, severe adverse reactions, lack of therapeutic efficacy.
Gentamicin B.Braun
Cross-contamination of infusion solutions in the specified batches of B. Braun medicinal products was detected and reported in the Rapid Alert system by the Hessian State Office for Health and Care. Potential effects: risk of incorrect dosing, toxicity, lack of therapeutic efficacy or serious complications after intravenous administration.
Gentamicin B.Braun
Cross-contamination of infusion solutions was identified in numerous batches of B. Braun products, meaning the presence of incorrect active substances or their residues in bottles intended for intravenous administration, breaching quality and safety requirements. Potential effects: severe adverse reactions, poisoning, lack of efficacy or complications of intravenous therapy.
Fluconazole B. Braun 2 mg/ml
Cross‑contamination of infusion solutions was detected in the above-mentioned medicinal product batches, which may lead to administration of an incorrect substance or dose to the patient. Potential effects: poisoning, serious adverse reactions, allergic reactions, lack of efficacy, severe systemic complications.
Amikacin B.Braun
Cross-contamination of infusion solutions in the listed medicinal product batches was detected, which may mean the presence of incorrect substances in the medicine. Potential effects: poisoning, lack of treatment efficacy, serious complications.
Amikacin B.Braun
Cross-contamination of infusion solutions was found in many batches of B. Braun medicinal products, which may mean the presence of an incorrect active substance or its traces in intravenously administered preparations. Potential effects: poisoning, severe adverse reactions, lack of treatment efficacy.
Amikacin B.Braun
Cross-contamination of infusion solutions was detected in the specified batches of medicinal products. Potential effects: poisoning, adverse reactions, infectious complications or lack of treatment efficacy.
Lactulose-MIP
A deviation in the manufacturing process was identified; deterioration of product quality during the shelf life cannot be excluded, thus creating a risk to patient health. Potential effects: lack of therapeutic efficacy or adverse reactions.
Sabril
The presence of tiapride above 0.3 ppm in vigabatrin products may theoretically lead to numerous serious and life‑threatening adverse reactions; a risk to the patient’s health or life cannot be excluded. Potential effects: serious adverse reactions, including life‑threatening events.
Sabril
Due to the detected presence of tiapride, a risk to the patient’s health or life cannot be excluded; the presence of trace amounts of tiapride may theoretically result in numerous serious and life‑threatening adverse reactions. Potential effects: severe, potentially life‑threatening adverse reactions.
Pasta borowinowa lecznicza
An excessive amount of Clostridium perfringens and the presence of Candida farmata/guilliermondii yeasts were detected, meaning the product does not meet microbiological purity requirements and may pose a health risk to patients when applied to the skin. Potential effects: skin infections, irritation, complications in immunocompromised individuals.
Tresuvi
Unidentified solid particles were detected in the solution for infusion; due to the unknown nature of the contamination, a risk to patients’ health and life cannot be excluded. Potential effects: thrombotic complications, emboli, inflammatory reactions, life-threatening events.
Andepin
Due to the detected increased content of a single impurity, a health risk for the patient taking this product cannot be excluded. Potential effects: poisoning, increased adverse reactions, complications of therapy.
Sirdalud MR
It is not possible to guarantee specification-compliant active substance release after 2 hours until the end of the shelf-life, which may affect the quality and safety of product use. Potential effects: lack of treatment efficacy or increased adverse effects.
Detimedac 500 mg
The pink discoloration may be caused by degradation of the active substance, which may pose an increased risk to the patient. Potential effects: lack of treatment efficacy, possible adverse reactions.
Detimedac 200 mg
The pink discoloration may be caused by degradation of the active substance, which may pose an increased risk to the patient. Potential effects: lack of treatment efficacy, complications of oncological therapy, possible adverse effects related to degradation products.
Detimedac 100 mg
Pink discoloration may be caused by degradation of the active substance, which may represent an increased risk to the patient. Potential effects: reduced treatment efficacy or unpredictable adverse reactions.
Duracef
Testing showed a lower value of cefadroxil release within 30 minutes, so a risk to patient health due to lack of drug efficacy cannot be excluded. Potential effects: lack of treatment effectiveness, possible disease complications.
Tirosint Sol
Due to the probability of reduced active substance content in the product, the risk to patient health resulting from decreased effectiveness of the medicine cannot be excluded. Potential effects: lack of treatment efficacy, disease worsening.
Tirosint Sol
Due to the probability of reduced active substance content in the product, the risk to patient health resulting from decreased effectiveness of the medicine cannot be excluded. Potential effects: reduced treatment effectiveness, worsening of disease symptoms.
Tirosint Sol
Due to the probability of reduced active substance content in the product, the risk to patient health resulting from decreased effectiveness of the medicine cannot be excluded. Potential effects: ineffective treatment, worsening of disease symptoms, complications resulting from thyroid hormone deficiency.
Tirosint Sol
Due to the probability of reduced active substance content in the product, the risk to patient health from decreased drug effectiveness cannot be excluded. Potential effects: lack of treatment efficacy, complications of the underlying disease.
Tirosint Sol
Due to the probability of a reduced content of the active substance in the product, the risk to patient health resulting from decreased effectiveness of the medicine cannot be excluded. Potential effects: ineffective treatment of hypothyroidism, worsening of disease symptoms.
Tirosint Sol
Due to the probability of reduced active substance content in the product, the risk to patient health resulting from decreased effectiveness of the medicine cannot be excluded. Potential effects: reduced treatment efficacy, disease complications, deterioration of health status.
Tirosint Sol
Due to the probability of reduced active substance content in the product, a risk to patient health resulting from decreased efficacy of the medicine cannot be excluded. Potential effects: reduced treatment efficacy, possible worsening of thyroid disease control.
Tirosint Sol
Due to the probability of reduced active substance content in the product, the risk to patient health resulting from decreased effectiveness of the medicine cannot be excluded. Potential effects: lack of efficacy in treating thyroid disorders, worsening of health status, possible complications of concomitant diseases.
Tirosint Sol
Due to the probability of reduced active substance content in the product, the risk to patient health resulting from decreased effectiveness of the medicine cannot be excluded. Potential effects: reduced treatment efficacy, possible worsening of thyroid disease symptoms.
Tirosint Sol
A probability of reduced content of the active substance – levothyroxine sodium – was identified in some batches, which may lead to insufficient treatment efficacy. Potential effects: lack of thyroid disease control, complications, worsened well-being.
Tirosint Sol
A probability of reduced content of the active substance – levothyroxine sodium – was identified, which prevents guaranteeing proper medicinal quality and may lead to reduced therapeutic efficacy. Potential effects: reduced treatment effectiveness, risk of exacerbation of thyroid disease symptoms.
Sirdalud MR
It was found that batch KDF58 does not meet the requirements for the mean value of tizanidine hydrochloride release at 2 hours, and the cause of this deviation is unknown, so the impact on product quality, safety of use and the risk to patients’ health cannot be predicted. Potential effects: overdose or insufficient drug effect, treatment complications.
Vectibix
The quality defect could cause leakage and loss of sterility of the medicine, creating a risk of microbial contamination and serious adverse reactions, posing a threat to the patient’s health and life. Potential effects: infection, severe complications, sepsis, life-threatening conditions.
Elocom
A risk was identified of placing on the market Elocom 1 mg/g cream packed in outer cartons for the “ointment” dosage form, causing labeling inconsistent with the contents and potentially misleading patients. Potential effects: improper use of the medicine, lack of expected efficacy, skin complications.
Elocom
A risk was identified that Elocom cream 1mg/g was marketed in outer cartons intended for the ointment, resulting in an incorrect description of the dosage form and uncertainty for patients. Potential effects: misuse of the medicine, lack of efficacy or increased adverse reactions.
Melisa Fix
The Chief Pharmaceutical Inspector states that the quality defect does not allow exclusion of the possibility of exceeding the acceptable daily intake limit of Stevia rebaudiana. Potential effects: adverse effects related to excessive intake, metabolic disturbances, lack of safe use.
Recalls by source
Frequently asked questions
What are GIF alerts?
GIF (Chief Pharmaceutical Inspectorate) alerts are decisions to suspend or withdraw medicines and pharmaceutical products from the market due to quality or safety issues.
What to do if you bought a recalled product?
Stop using or consuming the product immediately. Most recalled products can be returned to the store for a full refund, even without a receipt. On each alert page you will find a direct link to the official report with detailed information from the authorities.
What to do if you have this product?
A recall means the product may be unsafe. Here is what to do if you have it at home.
-
1
Do not eat or use the product
Stop using or consuming it immediately and keep it out of reach of children.
-
2
Check the batch number and expiry date
Compare the batch/lot number and the best-before or expiry date with the details in the alert — sometimes only specific batches are affected.
-
3
Return it to the shop
You can take the product back to the shop where you bought it. For a safety recall a refund is due even without a receipt.
-
4
Get help and report it
If you feel unwell after using the product, contact a doctor. You can also report the case to the relevant authority — GIS, GIF or UOKiK.
General guidance for recalled products in Poland. Always follow the specific instructions in the official alert and from the manufacturer or retailer.